PEPCK-C reexpression in the liver counters neonatal hypoglycemia in Pck1 del/del mice, unmasking role in non-gluconeogenic tissues

Semakova, Jana; Hyroššová, Petra; Méndez-Lucas, Andrés; Cutz, Ernest; Bermúdez, Jordi; Burgess, Shawn C.; Alcántara, Soledad; Perales, José C.

doi:10.1007/s13105-016-0528-y

Cited by 14 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCK1 is involved in gluconeogenesis and is a crucial enzyme in glucose metabolism in the body [19]. Indeed, PCK1-knockout mice die early after birth with profound hypoglycemia [20], which was partially rescued by the overexpression of PCK1 in the liver [21]. Therefore, gluconeogenesis under the control of PCK1 in the liver is crucial to avoid hypoglycemia.…”

Section: Discussionmentioning

confidence: 99%

Serum anti-PCK1 antibody levels are prognostic factor for the patients with diabetes mellitus

Namiki

Takemoto

Hayashi

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Autoantibodies develop in autoimmune diseases, cancer, diabetes mellitus (DM),and atherosclerosis-related diseases. However, autoantibody biomarkers have not been successfully examined for diagnosis and therapy. Methods: Serological identification of antigens through recombinant cDNA expression cloning (SEREX) was used for primary screening of antigens. The cDNA product was expressed in bacteria and purified. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) was used to evaluate antibody levels in serum samples. Results: Phosphoenolpyruvate carboxykinase 1 (PCK1) was recognized as an antigen by serum IgG antibodies in the sera of patients with atherosclerosis. AlphaLISA showed significantly higher serum antibody levels against recombinant PCK1 protein in patients with DM and cardiovascular diseasebut not in those with acute ischemic stroke, transient ischemic attack, or obstructive sleep apnea syndrome, than in healthy donors. The area under the receiver operating characteristic curve for anti-PCK1 antibodies was 0.7024 for DM. The serum anti-PCK1 antibody levels were associated with age, platelet count, and blood pressure. Anti-PCK1-antibody-positive patients showed significantly lower overall survival than the negative patients. Conclusions: Serum anti-PCK1 antibody levels were strongly associated with DM and weakly but significantly associated with cardiovascular disease. The anti-PCK1 antibody marker is useful for predicting the overall survival of patients with DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum anti-PCK1 antibody levels are prognostic factor for the patients with diabetes mellitus

Namiki

Takemoto

Hayashi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…PCK1 is involved in gluconeogenesis and is a crucial enzyme in glucose metabolism in the body [ 22 ]. Indeed, PCK1 -knockout mice die early after birth with profound hypoglycemia [ 23 ], which was partially rescued by the overexpression of PCK1 in the liver [ 24 ]. Therefore, gluconeogenesis under the control of PCK1 in the liver is crucial to avoid hypoglycemia.…”

Section: Discussionmentioning

confidence: 99%

Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus

Namiki,

Takemoto,

Hayashi

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Background Autoantibodies develop in autoimmune diseases, cancer, diabetes mellitus (DM), and atherosclerosis-related diseases. However, autoantibody biomarkers have not been successfully examined for diagnosis and therapy. Methods Serological identification of antigens through recombinant cDNA expression cloning (SEREX) was used for primary screening of antigens. The cDNA product was expressed in bacteria and purified. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) was used to evaluate antibody levels in serum samples. Results Phosphoenolpyruvate carboxykinase 1 (PCK1) was recognized as an antigen by serum IgG antibodies in the sera of patients with atherosclerosis. AlphaLISA showed significantly higher serum antibody levels against recombinant PCK1 protein in patients with DM and cardiovascular disease than in healthy donors, but not in those with acute ischemic stroke, transient ischemic attack, or obstructive sleep apnea syndrome. The area under the receiver operating characteristic curve for anti-PCK1 antibodies was 0.7024 for DM. The serum anti-PCK1 antibody levels were associated with age, platelet count, and blood pressure. Anti-PCK1-antibody-positive patients showed significantly lower overall survival than the negative patients. Conclusions Serum anti-PCK1 antibody levels were found to be associated with DM. The anti-PCK1 antibody marker is useful for predicting the overall survival of patients with DM.

show abstract

“…PCK1 catalyzed oxaloacetate to phosphoenolpyruvate via GTP and then released GDP for energy metabolism [79]. This biological process could produce glycerol to regulate adipogenesis [80]. Additionally, PCK1 was a target gene of PPARγ and regulated phosphoenolpyruvate through the PPARγ signaling pathway to affect the production of FAs [81], indicating PCK1 could interact with PPARγ to participate in the processes concerning fat deposition [82].…”

Section: Discussionmentioning

confidence: 99%

Transcriptomics and Lipid Metabolomics Analysis of Subcutaneous, Visceral, and Abdominal Adipose Tissues of Beef Cattle

Chang

et al. 2022

Genes

View full text Add to dashboard Cite

Fat deposition traits are influenced by genetics and environment, which affect meat quality, growth rate, and energy metabolism of domestic animals. However, at present, the molecular mechanism of fat deposition is not entirely understood in beef cattle. Therefore, the current study conducted transcriptomics and lipid metabolomics analysis of subcutaneous, visceral, and abdominal adipose tissue (SAT, VAT, and AAT) of Huaxi cattle to investigate the differences among these adipose tissues and systematically explore how candidate genes interact with metabolites to affect fat deposition. These results demonstrated that compared with SAT, the gene expression patterns and metabolite contents of VAT and AAT were more consistent. Particularly, SCD expression, monounsaturated fatty acid (MUFA) and triglyceride (TG) content were higher in SAT, whereas PCK1 expression and the contents of saturated fatty acid (SFA), diacylglycerol (DG), and lysoglycerophosphocholine (LPC) were higher in VAT. Notably, in contrast to PCK1, 10 candidates including SCD, ELOVL6, ACACA, and FABP7 were identified to affect fat deposition through positively regulating MUFA and TG, and negatively regulating SFA, DG, and LPC. These findings uncovered novel gene resources and offered a theoretical basis for future investigation of fat deposition in beef cattle.

show abstract

PEPCK-C reexpression in the liver counters neonatal hypoglycemia in Pck1 del/del mice, unmasking role in non-gluconeogenic tissues

Cited by 14 publications

References 22 publications

Serum anti-PCK1 antibody levels are prognostic factor for the patients with diabetes mellitus

Serum anti-PCK1 antibody levels are prognostic factor for the patients with diabetes mellitus

Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus

Transcriptomics and Lipid Metabolomics Analysis of Subcutaneous, Visceral, and Abdominal Adipose Tissues of Beef Cattle

Contact Info

Product

Resources

About